Khelwatty, S.A.; Puvanenthiran, S.; Essapen, S.; Bagwan, I.; Seddon, A.M.; Modjtahedi, H.
HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. Cancers 2021, 13, 638.
https://doi.org/10.3390/cancers13040638
AMA Style
Khelwatty SA, Puvanenthiran S, Essapen S, Bagwan I, Seddon AM, Modjtahedi H.
HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. Cancers. 2021; 13(4):638.
https://doi.org/10.3390/cancers13040638
Chicago/Turabian Style
Khelwatty, Said A., Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, and Helmout Modjtahedi.
2021. "HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer" Cancers 13, no. 4: 638.
https://doi.org/10.3390/cancers13040638
APA Style
Khelwatty, S. A., Puvanenthiran, S., Essapen, S., Bagwan, I., Seddon, A. M., & Modjtahedi, H.
(2021). HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. Cancers, 13(4), 638.
https://doi.org/10.3390/cancers13040638